For the 685,000 Americans living with alcohol-related cirrhosis, the prospect of meaningful liver recovery has long seemed remote once decompensation occurs. This paradigm may be shifting as hepatologists identify concrete pathways to hepatic recompensation—the restoration of stable liver function after severe deterioration. A comprehensive analysis across 17 medical centers tracked 633 patients with decompensated alcohol-related cirrhosis who achieved sustained abstinence, revealing that nearly one-third experienced clinically significant liver recovery. The cohort, predominantly male with a median age of 55, presented with advanced disease including median MELD scores of 19 and alcohol-associated hepatitis in 41% of cases. Rigorous recompensation criteria required sustained abstinence for at least three months, complete resolution of ascites and hepatic encephalopathy without ongoing therapy, absence of variceal bleeding for one year, and restoration to Child-Pugh A status or MELD scores below 10. Recovery rates accelerated over time, with 12% achieving recompensation within one year, climbing to 34% by five years. The timing of abstinence emergence as the most powerful predictor: patients who stopped drinking within one month of decompensation showed twice the likelihood of liver recovery compared to those with delayed cessation. Elevated liver enzymes—aspartate transaminase and gamma-glutamyltransferase—paradoxically predicted better outcomes, suggesting active hepatic repair processes respond favorably to alcohol withdrawal. These findings challenge the traditional fatalistic view of advanced alcohol-related liver disease. While recovery remains far from guaranteed, the data establish concrete biomarkers for identifying patients most likely to benefit from aggressive abstinence support, potentially transforming clinical decision-making in hepatology.